672 related articles for article (PubMed ID: 2375659)
21. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
22. The cytology of malignant mesothelioma in Western Australia.
Whitaker D; Shilkin KB
Acta Cytol; 1978; 22(2):67-70. PubMed ID: 276234
[TBL] [Abstract][Full Text] [Related]
23. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
Paintal A; Raparia K; Zakowski MF; Nayar R
Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
[TBL] [Abstract][Full Text] [Related]
24. [Thoracoscopy in pleural mesothelioma].
Zhang DH; Gu YT; Pan WS
Zhonghua Jie He He Hu Xi Za Zhi; 1993 Jun; 16(3):150-3, 187. PubMed ID: 8242812
[TBL] [Abstract][Full Text] [Related]
25. Cytologic presentation of malignant mesothelioma in pleural effusions.
Pedio G; Landolt-Weber U
Exp Cell Biol; 1988; 56(4):211-6. PubMed ID: 3203820
[TBL] [Abstract][Full Text] [Related]
26. [Clinical diagnosis of malignant pleural mesothelioma].
Yamamoto T; Morohoshi T; Nagashima T
Kyobu Geka; 2007 Jan; 60(1):10-3. PubMed ID: 17249531
[TBL] [Abstract][Full Text] [Related]
27. [Diagnostic difficulties in pleural mesothelioma].
Dubaniewicz A; Siemińska A
Wiad Lek; 1992 Apr; 45(7-8):248-50. PubMed ID: 1462582
[TBL] [Abstract][Full Text] [Related]
28. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells.
Westfall DE; Fan X; Marchevsky AM
Diagn Cytopathol; 2010 Jan; 38(1):9-14. PubMed ID: 19626629
[TBL] [Abstract][Full Text] [Related]
29. [Malignant diffuse pleural mesothelioma confirming diagnosis].
Calavrezos A; Hain E
Dtsch Med Wochenschr; 1982 Jun; 107(23):903-6. PubMed ID: 7084057
[No Abstract] [Full Text] [Related]
30. [Pleural mesothelioma--case with effusion in both pleural cavities].
Fijałkowski M; Jochymski C
Pol Merkur Lekarski; 2004 Nov; 17(101):479-82. PubMed ID: 15754636
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
32. Image cytometry: an aid for cytological diagnosis of pleural effusions.
Osterheld MC; Liette C; Anca M
Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
[TBL] [Abstract][Full Text] [Related]
33. [Primary malignant mesothelioma of the pericardium masquerading as malignant pleural mesothelioma: report of an autopsy case and review of the reported cases in Japan as to its invasion to neighboring organs].
Torii T; Takasuga H; Mizushima M; Ito J; Kanaya T; Matsushima T
Kokyu To Junkan; 1989 Sep; 37(9):1027-32. PubMed ID: 2687998
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and cytological features of diffuse mesotheliomas of the pleura.
Matzel W
Arch Geschwulstforsch; 1985; 55(4):259-64. PubMed ID: 4037997
[TBL] [Abstract][Full Text] [Related]
35. [Localized fibrous mesothelioma with bloody pleural effusion; report of a case].
Ogata K; Sakakibara K; Hirano R; Nishiumi N; Tsutsumi M; Ishihara S; Namikawa S
Kyobu Geka; 2004 Feb; 57(2):159-62. PubMed ID: 14978915
[TBL] [Abstract][Full Text] [Related]
36. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
[TBL] [Abstract][Full Text] [Related]
37. [The role of pleural effusion cytology in the diagnosis of malignancies].
Mermolja M; Debeljak A
Plucne Bolesti; 1989; 41(3-4):146-9. PubMed ID: 2636394
[TBL] [Abstract][Full Text] [Related]
38. [Malignant mesothelioma with osteoblastic heterologous elements].
Chalabreysse L; Guillaud C; Tabib A; Loire R; Thivolet-Béjui F
Ann Pathol; 2001 Oct; 21(5):428-30. PubMed ID: 11852361
[TBL] [Abstract][Full Text] [Related]
39. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
40. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
